Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30155391 | 1.00 | CYP1A2 (0.52) | CYP1A2TDP1ATMP2RY6CCR6 | |
| SCHEMBL4748223 | 0.86 | TDP1 (0.54) | CYP1A2TDP1ATMCCR6L3MBTL1 | |
| SCHEMBL4019558 | 0.82 | CYP1A2 (0.37) | CYP1A2TDP1ATMP2RY6L3MBTL1 | |
| SCHEMBL30829764 | 0.80 | TDP1 (0.53) | CYP1A2TDP1ATMCCR6L3MBTL1 | |
| SCHEMBL10685212 | 0.80 | CYP1A2 (0.55) | CYP1A2TDP1ATMCCR6L3MBTL1 | |
| SCHEMBL3460888 | 0.80 | TDP1 (0.53) | CYP1A2TDP1ATMCCR6L3MBTL1 | |
| SCHEMBL2132590 | 0.80 | TDP1 (0.44) | CYP1A2TDP1ATMP2RY6L3MBTL1 | |
| SCHEMBL29617721 | 0.80 | TDP1 (0.44) | CYP1A2TDP1ATMP2RY6L3MBTL1 | |
| SCHEMBL22968279 | 0.80 | GPR35 (0.55) | CYP1A2TDP1CCR6L3MBTL1MEN1 | |
| SCHEMBL629542 | 0.80 | CYP1A2 (0.55) | CYP1A2TDP1CCR6ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283659-B | Preparation method and application of m-nitrobenzonitrile | 上海忝晴化工有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-116283659-A | Preparation method and application of m-nitrobenzonitrile | 上海忝晴化工有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-11673868-B2 | Amino pyrimidine derivatives | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | claimed |
| US-20220041561-A1 | Amino Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-02-10 | — | — | US | claimed |
| US-20260103453-A1 | NOVEL PYRIMIDINE DERIVATIVE AS BRUTON'S TYROSINE KINASE INHIBITOR | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-16 | — | — | US | disclosed |
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | PI INDUSTRIES LTD. (IN) | 2026-02-10 | — | — | US | disclosed |
| EP-4647426-A2 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI Industries Ltd. (IN) | 2025-11-12 | — | — | EP | disclosed |
| US-12466813-B2 | PRC1 inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4606377-A2 | NOVEL AMINO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4602035-A1 | NOVEL PYRIMIDINE DERIVATIVE AS BRUTON'S TYROSINE KINASE INHIBITOR | Hanmi Pharm. Co., Ltd. (KR) | 2025-08-20 | — | — | EP | disclosed |
| US-12391681-B2 | (R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases | PHARVARIS GMBH (CH) | 2025-08-19 | — | — | US | disclosed |
| EP-4155293-B1 | PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITH | UNIV MICHIGAN REGENTS (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007072041-A1 | THERAPEUTIC COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007072041-A1 | THERAPEUTIC COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-08 | — | — | US | disclosed |
| WO-2007023110-A2 | P38 MAP KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041561-A1 | Amino Pyrimidine Derivatives | BTK, LCK, JAK1 | CYP1A2 3752/4885TDP1 858/4885ATM 181/4885 |
| US-12466813-B2 | PRC1 inhibitors and methods of treatment therewith | BMI1, EZH2, CBX3 | CYP1A2 4618/4885TDP1 2122/4885ATM 2199/4885 |
| US-20260103453-A1 | NOVEL PYRIMIDINE DERIVATIVE AS BRUTON'S TYROSINE KINASE INHIBITOR | BTK, LYN, LCK | CYP1A2 3773/4885TDP1 273/4885ATM 701/4885 |
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | CBR1, CBR3, HCCS | CYP1A2 365/4885TDP1 3645/4885ATM 3098/4885 |
| US-12391681-B2 | (R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseases | BDKRB2, BDKRB1, BRCA1 | CYP1A2 477/4885TDP1 3147/4885ATM 344/4885 |
| US-20070054915-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K7 | CYP1A2 2209/4885TDP1 519/4885ATM 356/4885 |
| US-11673868-B2 | Amino pyrimidine derivatives | BTK, LCK, JAK1 | CYP1A2 3847/4885TDP1 941/4885ATM 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.